메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Sore Back After Pre-New Year Cleaning? Herbalgy's "Wellness Declutter" Method Shares 3 Tips to Sweep Away Pain for a Light, Energetic New Year

HONG KONG, Feb. 5, 2026 -- As Lunar New Year approaches, many households dive into their annual deep cleaning, hoping to start the year in a fresh, orderly environment. However, intensive cleaning in a short period—repeated bending, squatting, kneeling, or lifting, can quickly lead to stiff shoulders, sore backs, and general discomfort, sometimes to the point of spoiling holiday enjoyment. From a Traditional Chinese Medicine (TCM) perspective, such discomfort often stems from "tendon-muscle strain" and "qi stagnation and blood stasis." With proper preparation, corr
- 김갑성 기자
- 2026-02-05 22:38
LifeZoom Introduces the Oclux Red Light Eye Mask--A Naturally Restorative, Aesthetics-Driven Solution for the Effects of Screen-Based Life

NEW YORK, Feb. 5, 2026 -- LifeZoom, a natural-restorative brand, today launches Oclux, a red light eye mask that expands the company's red light product lineup. Positioned as a holistic solution that balances visual aesthetics, user experience, and daily rhythms, Oclux is designed to help relieve the physical and mental imbalances associated with modern lifestyles and to guide users back toward a more instinctive state of rest. The Oclux red light therapy eye mask is designed to help relieve the physical and mental imbalances associated with modern lifestyles and to guide users ba
- 김갑성 기자
- 2026-02-05 22:12
Jin Medical CEO Fireside Chat

CHANGZHOU, China, Feb. 5, 2026 -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat on February 2, 2026 where the CEO shared some insights into the Company's recent strategic priorities and long-term growth considerations. The following questions were prepared by the Company and addressed by the Company's CEO, Dr. Erqi Wang during the conversation. Certain statements made during the discussion were forward
- 김갑성 기자
- 2026-02-05 21:57
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

[ 메디채널 김갑성 기자 ] NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike ISM8969, Insilico's brain-penetrant NLRP3 pipeline already with FDA IND clearance, ISM5059 features a completely different chemical core designed for peripheral-restricted potency. Empowered by AI, ISM5059 demonstrated robust efficacy, excellent safety profiles in preclinical studies, and low predicted human efficacious dose,
- 김갑성 기자
- 2026-02-05 21:00
Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors

[ 메디채널 김갑성 기자 ] Leah Goodman brings a wealth of policy and regulatory experience and is a recognized leader in Australia for advancing scientific discoveries to patient impacts. CALGARY, AB and BRISBANE, Australia, Feb. 5, 2026 -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors, is pleased to welcome Leah Goodman to the Board of Directors. Since late 2023, Leah Goodman has served as Chief Exe
- 김갑성 기자
- 2026-02-05 21:00
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb. 5, 2026 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan. Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode t
- 김갑성 기자
- 2026-02-05 19:44
Leading Chinese Innovative Medical Device Maker Insight Lifetech Has Successfully Listed on STAR Market

SHANGHAI, Feb. 5, 2026 -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) issued shares at a price of CNY17.52 per share and opened at CNY50.31 per share with a market capitalization of CNY20.98 billion. Qiming Venture Partners led the C round financing of Insight Lifetech in 2020 and continued to fund the company's development in the D round. Before the company's IPO, Qiming Ventur
- 김갑성 기자
- 2026-02-05 19:39
HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

[ 메디채널 김갑성 기자 ] Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical
- 김갑성 기자
- 2026-02-05 17:09
Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism

BEIJING, Feb. 5, 2026 -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study in Nature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological mechanism of PD and provide a scientific basis for developing precision neural circuit stimulation strategies for treating the condition. PD currently affects over 13 million people worldwide and continues to pose a major clinical challenge, as existing treatments ranging from long-term medication
- 김갑성 기자
- 2026-02-05 13:00
Moleac is pleased to announce that NeuroAiD™II has been awarded Gold accreditation by Empowered By Evidence.

SINGAPORE, Feb. 5, 2026 -- This recognition reflects the robust clinical evidence supporting NeuroAiD™II, as well as the uniqueness of its formulation, the rigour of its manufacturing, reproducibility, and quality control, highlighting its reliability and value in supporting neurological disorders. Empowered By Evidence (EBE) is an independent, international non-profit organisation, founded in 2014 and based in New York. Its panel of natural health specialists and researchers applies a transparent, science-led process to evaluate natural health products, helping healthcare professional
- 김갑성 기자
- 2026-02-05 11:48

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 01시 00분